Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorPiñana, J.L.
dc.contributor.authorXhaard, A.
dc.contributor.authorTridello, G.
dc.contributor.authorPassweg, J.
dc.contributor.authorKozijn, A.
dc.contributor.authorPolverelli, N.
dc.contributor.authorHeras, I.
dc.date.accessioned2021-06-10T19:38:18Z
dc.date.available2021-06-10T19:38:18Z
dc.date.issued2021
dc.identifier.issn1537-6613
dc.identifier.urihttps://doi.org/10.1093/infdis/jiaa553
dc.identifier.urihttp://hdl.handle.net/11446/4284
dc.descriptionPubMed: 32860509en_US
dc.description2-s2.0-85107087117en_US
dc.description.abstractBACKGROUND: Little is known about characteristics of seasonal human coronaviruses (HCoVs) (NL63, 229E, OC43, and HKU1) after allogeneic stem cell transplantation (allo-HSCT). METHODS: This was a collaborative Spanish and European bone marrow transplantation retrospective multicenter study, which included allo-HSCT recipients (adults and children) with upper respiratory tract disease (URTD) and/or lower respiratory tract disease (LRTD) caused by seasonal HCoV diagnosed through multiplex polymerase chain reaction assays from January 2012 to January 2019. RESULTS: We included 402 allo-HSCT recipients who developed 449 HCoV URTD/LRTD episodes. Median age of recipients was 46 years (range, 0.3-73.8 years). HCoV episodes were diagnosed at a median of 222 days after transplantation. The most common HCoV subtype was OC43 (n?=?170 [38%]). LRTD involvement occurred in 121 episodes (27%). HCoV infection frequently required hospitalization (18%), oxygen administration (13%), and intensive care unit (ICU) admission (3%). Three-month overall mortality after HCoV detection was 7% in the whole cohort and 16% in those with LRTD. We identified 3 conditions associated with higher mortality in recipients with LRTD: absolute lymphocyte count <0.1 × 109/mL, corticosteroid use, and ICU admission (hazard ratios: 10.8, 4.68, and 8.22, respectively; P?<?.01). CONCLUSIONS: Seasonal HCoV after allo-HSCT may involve LRTD in many instances, leading to a significant morbidity. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.en_US
dc.language.isoengen_US
dc.publisherNLM (Medline)en_US
dc.identifier.doi10.1093/infdis/jiaa553en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectseasonal human coronavirusen_US
dc.subjectallogeneic hematopoietic stem cell transplantationen_US
dc.subjectcommunity-acquired respiratory virusen_US
dc.subjectHCoV-229Een_US
dc.subjectHCoV-HKU1en_US
dc.subjectHCoV-NL63en_US
dc.subjectHCoV-OC43en_US
dc.subjectimmunocompromiseden_US
dc.subjectimmunodeficiency score indexen_US
dc.subjectmultiplex PCR assayen_US
dc.subjectupper and lower respiratory tract diseaseen_US
dc.titleSeasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantationen_US
dc.typearticleen_US
dc.relation.journalThe Journal of infectious diseasesen_US
dc.department[0-Belirlenecek]en_US
dc.identifier.issue9en_US
dc.identifier.volume223en_US
dc.identifier.startpage1564en_US
dc.identifier.endpage1575en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.institutionauthor[0-Belirlenecek]
dc.department-tempPiñana, J.L., Hematology Division, Hospital Universitario y Politécnico La FeValencia, Spain, Instituto Carlos IIIMadrid, Spain; Xhaard, A., Service d'Hématologie-Greffe, Hôpital Saint-Louis, Université Paris-Diderot, Paris, France; Tridello, G., Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy; Passweg, J., University Hospital Basel, Basel, Switzerland; Kozijn, A., European Society for Blood and Marrow Transplantation Data Office Leiden, Leiden, Netherlands; Polverelli, N., Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy; Heras, I., Hematology Division, Hospital Morales MeseguerMurcia, Spain; Perez, A., Hematology Division, Hospital Clínico de ValenciaValencia, Spain; Sanz, J., Hematology Division, Hospital Universitario y Politécnico La FeValencia, Spain, Instituto Carlos IIIMadrid, Spain; Berghuis, D., Willem Alexander Children's Hospital/Leiden University Medical Center, Leiden, Netherlands; Vázquez, L., Hematology Division, Hospital Universitario de Salamanca, Salamanca, Spain; Suárez-Lledó, M., Hematology Division, Hospital Clínic, Barcelona, Spain; Itäla-Remes, M., Turku University Hospital, Turku, Finland; Ozcelik, T., Demiroglu Bilim UniversityIstanbul, Turkey; Iturrate Basarán, I., Hematology Division, Hospital de la PrincesaMadrid, Spain; Karakukcu, M., Erciyes University, Faculty of Medicine, Erciyes Pediatric Bone Marrow Transplant CenterKayseri, Turkey; Al Zahrani, M., King Abdulaziz Medical City, Riyadh, Saudi Arabia; Choi, G., University Medical Center Groningen, University of GroningenGroningen, Netherlands; Cuesta Casas, M.A., Hematology Division, Hospital Regional de Málaga, Malaga, Spain; Batlle Massana, M., Hematology Division, Instituto Catalan de Oncologia-Hospital Germans Trias i Pujol, Barcelona, Spain; Viviana, A., Universita Cattolica S. Cuore, Rome, Italy; Blijlevens, N., Radboud University Medical Center, Nijmegen, Netherlands; Ganser, A., Department of Hematology, Hemostasis, Oncology, Stem Cell Transplantation. Hannover Medical School, Hannover, Germany; Kuskonmaz, B., Hacettepe University Children's HospitalAnkara, Turkey; Labussière-Wallet, H., Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Shaw, P.J., Children's Hospital at Westmead, Sydney, Australia; Arzu Yegin, Z., Gazi University Faculty of MedicineAnkara, Turkey; González-Vicent, M., Pediatric Division, Niño Jesus Children's HospitalMadrid, Spain; Rocha, V., Hospital Sirio-Libanes, São Paulo, Brazil; Ferster, A., Children's University Hospital Queen Fabiola, Université Libre de Bruxelles, Brussels, Belgium; Knelange, N., Service d'Hématologie-Greffe, Hôpital Saint-Louis, Université Paris-Diderot, Paris, France; Navarro, D., Hematology Division, Hospital Morales MeseguerMurcia, Spain; Mikulska, M., University of Genoa (Dipartimento di Scienze della Salute) and Istituto Nazionale per la Ricerca sul Cancro Ospedale Policlinico San Martino, Genova, Italy; de la Camara, R., Hematology Division, Hospital de la PrincesaMadrid, Spain; Styczynski, J., Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun Uniwersytet Miko?aja Kopernika, University Hospital, Bydgoszcz, Polanden_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster